{"success":true,"data":{"pressRelease":{"id":"95617","rtpr_id":"nGNX4QbPcp","ticker":"CHRS","exchange":"NASDAQ","all_tickers":["CHRS"],"title":"Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026","author":"Globe Newswire","published_at":"2026-07-22T17:36:25.101Z","article_body":"REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology,\nInc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial\nresults will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m.\nEastern Daylight Time on August 5, 2026, Coherus’ management team will host\na conference call and webcast to discuss financial results and provide a\ngeneral business update.\n\nA webcast replay will be available on https://investors.coherus.com following\nthe conclusion of the live conference call.\n\nConference Call Information\n\nWhen: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight Time.\n\nTo access the conference call, please pre-register through the following link\nto receive dial-in information and a personal PIN to access the live call:\nhttps://register-conf.media-server.com/register/BId137c93eda7d4cf0b60be1df98d9b99f\n\nWebcast: https://edge.media-server.com/mmc/p/vhd7ef6h\n\nThe press release with the second quarter 2026 financial results and related\nmaterials will be available at https://investors.coherus.com before the start\nof the conference call.\n\nA live and archived webcast will be available on the “Investors” section\nof the Coherus website at https://investors.coherus.com/events-presentations.\n\nPlease dial in 15 minutes early to ensure a timely connection to the call.\n\nDisclosure Information\n\nCoherus uses the https://investors.coherus.com website as a means of\ndisclosing material non-public information and for complying with its\ndisclosure obligations under Regulation FD. \n\nAbout Coherus Oncology\n\nCoherus Oncology is a fully integrated commercial-stage innovative oncology\ncompany with an approved next-generation programmed death receptor-1\n(“PD-1”) inhibitor, LOQTORZI(® )(toripalimab-tpzi), and a pipeline that\nincludes two mid-stage clinical candidates targeting liver, prostate, head &\nneck, colorectal and other cancers. The Company’s strategy is to grow sales\nof LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its\ntwo pipeline candidates in combination with LOQTORZI and through strategic\npartnerships.\n\nCoherus’ innovative oncology pipeline includes multiple antibody\nimmunotherapy candidates focused on enhancing the innate and adaptive immune\nresponses to enable a robust antitumor response and improve outcomes for\npatients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8\nantibody currently in Phase 1b/2a studies in patients with advanced solid\ntumors; including head and neck squamous cell carcinoma, colorectal cancer,\ngastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal\nsquamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody\ncurrently being evaluated in a Phase 2 study in patients with first-line\nhepatocellular carcinoma.\n\nLOQTORZI(® )is a registered trademark of Coherus Oncology, Inc.\n©2026 Coherus Oncology, Inc. All rights reserved.\n\nCoherus Oncology Contact Information:\n\nFor Investors:\n\nCarrie Graham\nVice President, Investor Relations & Advocacy\nIR@coherus.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/07437af0-8ae3-48cf-952b-18bc6b99ca7c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4QbPcp","title":"Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026","author":"Globe Newswire","ticker":"CHRS","created":"2026-07-22T17:36:25.101Z","tickers":["CHRS"],"exchange":"NASDAQ","article_body":"REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology,\nInc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial\nresults will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m.\nEastern Daylight Time on August 5, 2026, Coherus’ management team will host\na conference call and webcast to discuss financial results and provide a\ngeneral business update.\n\nA webcast replay will be available on https://investors.coherus.com following\nthe conclusion of the live conference call.\n\nConference Call Information\n\nWhen: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight Time.\n\nTo access the conference call, please pre-register through the following link\nto receive dial-in information and a personal PIN to access the live call:\nhttps://register-conf.media-server.com/register/BId137c93eda7d4cf0b60be1df98d9b99f\n\nWebcast: https://edge.media-server.com/mmc/p/vhd7ef6h\n\nThe press release with the second quarter 2026 financial results and related\nmaterials will be available at https://investors.coherus.com before the start\nof the conference call.\n\nA live and archived webcast will be available on the “Investors” section\nof the Coherus website at https://investors.coherus.com/events-presentations.\n\nPlease dial in 15 minutes early to ensure a timely connection to the call.\n\nDisclosure Information\n\nCoherus uses the https://investors.coherus.com website as a means of\ndisclosing material non-public information and for complying with its\ndisclosure obligations under Regulation FD. \n\nAbout Coherus Oncology\n\nCoherus Oncology is a fully integrated commercial-stage innovative oncology\ncompany with an approved next-generation programmed death receptor-1\n(“PD-1”) inhibitor, LOQTORZI(® )(toripalimab-tpzi), and a pipeline that\nincludes two mid-stage clinical candidates targeting liver, prostate, head &\nneck, colorectal and other cancers. The Company’s strategy is to grow sales\nof LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its\ntwo pipeline candidates in combination with LOQTORZI and through strategic\npartnerships.\n\nCoherus’ innovative oncology pipeline includes multiple antibody\nimmunotherapy candidates focused on enhancing the innate and adaptive immune\nresponses to enable a robust antitumor response and improve outcomes for\npatients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8\nantibody currently in Phase 1b/2a studies in patients with advanced solid\ntumors; including head and neck squamous cell carcinoma, colorectal cancer,\ngastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal\nsquamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody\ncurrently being evaluated in a Phase 2 study in patients with first-line\nhepatocellular carcinoma.\n\nLOQTORZI(® )is a registered trademark of Coherus Oncology, Inc.\n©2026 Coherus Oncology, Inc. All rights reserved.\n\nCoherus Oncology Contact Information:\n\nFor Investors:\n\nCarrie Graham\nVice President, Investor Relations & Advocacy\nIR@coherus.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/07437af0-8ae3-48cf-952b-18bc6b99ca7c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-22T17:36:25.135847471Z","server_sent_at_ms":1784741785135},"received_at":"2026-07-22T17:36:25.188Z","source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331650/33333/en/Coherus-Oncology-to-Report-Second-Quarter-2026-Financial-Results-on-August-5-2026.html"},"analysis":{"id":"84659","press_release_id":"95617","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Coherus Oncology scheduled the release of its second quarter 2026 financial results for Wednesday, August 5, 2026.\n\nManagement will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time on that date to discuss the results and provide a business update.\n\nA replay of the webcast will be available on the company's investor relations website following the live event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings date confirmation"},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Carrie Graham","role":"Vice President, Investor Relations & Advocacy"}],"products":["LOQTORZI (toripalimab-tpzi)","Tagmokitug","Casdozokitug"],"companies":[{"name":"Coherus Oncology, Inc.","ticker":"CHRS"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine scheduling announcement for an upcoming earnings release and conference call. No financial results or material business updates are provided in this release."},"tickerRelevance":{"others":[],"primary":"CHRS"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid_cap","eventGravity":"routine_earnings_scheduling"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Coherus Oncology scheduled the release of its second quarter 2026 financial results for Wednesday, August 5, 2026.\n\nManagement will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time on that date to discuss the results and provide a business update.\n\nA replay of the webcast will be available on the company's investor relations website following the live event.","key_figures":null,"named_entities":{"people":[{"name":"Carrie Graham","role":"Vice President, Investor Relations & Advocacy"}],"products":["LOQTORZI (toripalimab-tpzi)","Tagmokitug","Casdozokitug"],"companies":[{"name":"Coherus Oncology, Inc.","ticker":"CHRS"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-22T20:01:55.604Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"mid_cap","eventGravity":"routine_earnings_scheduling"}},"durationMs":355032,"modelName":"glm-4.7"}}